BioSpace News Archive

Business

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

January 23, 2024
·
1 min read
BioCapital

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1, 2024.

January 23, 2024
·
2 min read
Genetown

ReLive Biotechnologies Announces NDA Approval of SpheChon 10-70 spheroids/cm² by the HSA in Singapore, Marking a Milestone in ReLive’s Global Endeavors

ReLive is proud to announce that the Health Sciences Authority (HSA), Singapore’s highest health authority, has granted New Drug Application (NDA) approval for SpheChon 10-70 spheroids/cm² in December 2023, marking the country’s first cell therapy product for cartilage repair in its history.

January 23, 2024
·
2 min read
Biotech Bay

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors.

January 23, 2024
·
1 min read
Policy

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics, Inc. announced it has terminated its previously announced “at-the-market” equity offering program.

January 23, 2024
·
2 min read
Business

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors

Citius Pharmaceuticals, Inc. today announced the nomination of seasoned pharmaceutical executive Robert J. Smith to its Board of Directors.

January 23, 2024
·
7 min read
Biotech Beach

Crown Bioscience’s Global Oncology Research Facilities Achieve Prestigious ISO and CAP Accreditations

Crown Bioscience , a global contract research organization (CRO) and JSR Life Sciences company, proudly announces that its global laboratory facilities have successfully passed a series of annual on-site ISO audits, achieving a flawless record with zero discrepancies.

January 23, 2024
·
2 min read
Business

Vivtex Enters Research Collaboration with Astellas Pharma

Vivtex Corporation announces that it has entered a research collaboration with Astellas Pharma Inc. (“Astellas”), a global pharmaceutical company.

January 23, 2024
·
2 min read
Deals

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement a 1-for-30 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2024.

January 23, 2024
·
5 min read
BioCapital

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease.

January 23, 2024
·
5 min read